Anki Malmborg Hager
Director/Board Member at SENZAGEN AB
Profile
Cecilia Ann-Christin Malmborg Hager is currently the Chief Executive Officer & Director at Pain Drainer AB since 2019.
She is also a Non-Independent Director at SenzaGen AB since 2014.
Additionally, she holds director positions at Diaprost AB, Hager Consulting AB, Avena Partners AB, Nanoecho AB, Colzyx AB, and Lead Biologics International AB.
In her former roles, Dr. Malmborg Hager served as the Chief Executive Officer at WC Likvid AB.
She was also the Chief Executive Officer & Director at Cantargia AB from 2013 to 2014.
She held the position of Chief Executive Officer at Sista versen 26366.
AB and Executive Foundation Lund.
Furthermore, she was the Chief Executive Officer at Xlmmune AB.
Prior to that, she worked as an Investment Director at Lund University Bioscience AB from 2009 to 2011.
She also served as an Independent Director at Immunovia AB and as a Director & Business Manager at ProNoxis AB.
Additionally, she held director positions at Bulb Intelligence AB and served as the Vice President-Business Development at Alligator Bioscience AB.
Dr. Malmborg Hager obtained her graduate and doctorate degrees from the University of Lund.
Anki Malmborg Hager active positions
| Companies | Position | Start |
|---|---|---|
| SENZAGEN AB | Director/Board Member | 2019-06-16 |
| Hager Consulting AB | Director/Board Member | - |
| Nanoecho AB | Director/Board Member | - |
Pain Drainer AB
 Pain Drainer AB Internet Software/ServicesTechnology Services Pain Drainer AB operates an artificial intelligence drug-free self-management tool for chronic pain patients. The private company is based in Stockholm, Sweden. Cecilia Ann-Christin Malmborg Hager has been the CEO of the Swedish company since 2019. | Chief Executive Officer | 2019-08-31 |
| Avena Partners AB | Director/Board Member | - |
Diaprost AB
 Diaprost AB Miscellaneous Commercial ServicesCommercial Services Diaprost AB is a private pharmaceutical research and development company based in Lund, Sweden. Diaprost collaborates with leading international experts in the fields of molecular medicine, biotechnology, immunology, radiology, radiation physics, laboratory medicine, and oncology. The Swedish company has an agreement with a top 10 pharma company for its first antibody H11B6 targeting the HK2 antigen, which is in early clinical development. The remaining Diaprost pipeline consists of 5A10, which targets free-PSA antigen for both diagnostic and therapeutic applications. The company was founded in 2005 with the aim of leveraging the transformative success of the PSA assay for detection of prostate cancer as a personalized theranostic platform. Johan Drott has been the CEO of the company since 2015. | Director/Board Member | - |
Colzyx AB
 Colzyx AB Medical SpecialtiesHealth Technology Colzyx AB is a biotechnology company located in Lund, Sweden. The Swedish company specializes in wound care and have developed a new wound dressing called Woundcom. This innovative product not only accelerates wound healing but also has an antibacterial effect. The private company has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement no. 947034. | Director/Board Member | - |
Former positions of Anki Malmborg Hager
| Companies | Position | End |
|---|---|---|
Lund University Bioscience AB
 Lund University Bioscience AB Investment ManagersFinance Lund University Bioscience AB (LU Bio) is an investment firm located in Lund, Sweden. In May 2007, LU Bio was founded by the parent firm, Lund University Development AB. They specialize in early-stage investments within the life sciences segment. Lund University was founded by the Swedish government in 1666. The university has three main research areas: medicine and pharmaceuticals, globally sustainable societal development, and the life sciences. | Chief Investment Officer | - |
ProNoxis AB
 ProNoxis AB Pharmaceuticals: MajorHealth Technology ProNoxis AB develops small-molecule drugs to treat chronic inflammation. The company was founded in 2009 and is headquartered in Lund, Sweden. | Director/Board Member | - |
| ░░ ░░░░░░ ░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░ ░░░░░ ░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - |
| ░░░░░░░░░ ░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Training of Anki Malmborg Hager
| University of Lund | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| ALLIGATOR BIOSCIENCE AB | Health Technology |
| IMMUNOVIA AB | Health Technology |
| CANTARGIA AB | Health Technology |
| SENZAGEN AB | Health Technology |
| Private companies | 12 |
|---|---|
Lund University Bioscience AB
Lund University Bioscience AB Investment ManagersFinance Lund University Bioscience AB (LU Bio) is an investment firm located in Lund, Sweden. In May 2007, LU Bio was founded by the parent firm, Lund University Development AB. They specialize in early-stage investments within the life sciences segment. Lund University was founded by the Swedish government in 1666. The university has three main research areas: medicine and pharmaceuticals, globally sustainable societal development, and the life sciences. | Finance |
ProNoxis AB
ProNoxis AB Pharmaceuticals: MajorHealth Technology ProNoxis AB develops small-molecule drugs to treat chronic inflammation. The company was founded in 2009 and is headquartered in Lund, Sweden. | Health Technology |
WC Likvid AB
 WC Likvid AB Real Estate DevelopmentFinance WC Likvid AB owns and manages movable and immovable property. The company was founded by Tadeusz Wojciech Wieloch on June 5, 2009 and is headquartered in Staffanstorp, Sweden. | Finance |
Sista versen 26366 AB
 Sista versen 26366 AB Pharmaceuticals: MajorHealth Technology Sista Versen 26366 AB discovers treatments for inflammatory disorders. Their treatment is based on properties of new classes of endogenous host defense peptides from proteins within the coagulation cascade, which display potent immune-modulating properties. The firm develops drugs that prevent sepsis development. The company was founded by Artur Schmidtchen and Nils Martin Malmsten on October 26, 2009 and is headquartered in Lund, Sweden. | Health Technology |
Diaprost AB
Diaprost AB Miscellaneous Commercial ServicesCommercial Services Diaprost AB is a private pharmaceutical research and development company based in Lund, Sweden. Diaprost collaborates with leading international experts in the fields of molecular medicine, biotechnology, immunology, radiology, radiation physics, laboratory medicine, and oncology. The Swedish company has an agreement with a top 10 pharma company for its first antibody H11B6 targeting the HK2 antigen, which is in early clinical development. The remaining Diaprost pipeline consists of 5A10, which targets free-PSA antigen for both diagnostic and therapeutic applications. The company was founded in 2005 with the aim of leveraging the transformative success of the PSA assay for detection of prostate cancer as a personalized theranostic platform. Johan Drott has been the CEO of the company since 2015. | Commercial Services |
| Hager Consulting AB | |
| Avena Partners AB | |
| Bulb Intelligence AB | |
Xlmmune AB
 Xlmmune AB Pharmaceuticals: MajorHealth Technology Xlmmune AB is a Swedish pharmaceutical company that specializes in pharmaceutical preparation. The private company is based in Lund, Sweden. | Health Technology |
Pain Drainer AB
Pain Drainer AB Internet Software/ServicesTechnology Services Pain Drainer AB operates an artificial intelligence drug-free self-management tool for chronic pain patients. The private company is based in Stockholm, Sweden. Cecilia Ann-Christin Malmborg Hager has been the CEO of the Swedish company since 2019. | Technology Services |
| Nanoecho AB | |
Colzyx AB
Colzyx AB Medical SpecialtiesHealth Technology Colzyx AB is a biotechnology company located in Lund, Sweden. The Swedish company specializes in wound care and have developed a new wound dressing called Woundcom. This innovative product not only accelerates wound healing but also has an antibacterial effect. The private company has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement no. 947034. | Health Technology |
- Stock Market
- Insiders
- Anki Malmborg Hager
